Pancreatic cancer pill shrinks tumours in six in 10 patients in early trial
A daily pill combined with chemotherapy halted tumour growth in 90% of 61 patients with advanced pancreatic cancer in an early trial, with tumours undetectable on scans in about one in 12.
A daily pill taken alongside chemotherapy has stopped tumour growth in about nine in 10 patients with advanced pancreatic cancer, with the disease becoming undetectable on scans in one in 12, early trial results show.
Experts are calling it the biggest breakthrough in pancreatic cancer treatment for decades. The drug, daraxonrasib, was given with the chemotherapy drugs gemcitabine and nabpaclitaxel to 61 patients who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body. The results were presented at a European cancer conference in Barcelona.
In the phase I/II trial, tumours stopped growing in 90% of patients. Just over 60% saw their tumours shrink or disappear, and for around 8% of patients, or one in 12, tumours became undetectable on CT scans. Patients were followed for around 18 months, and 76.6% were still alive a year after starting treatment.
Cancer Research UK called it “the biggest leap forward in decades” for pancreatic cancer patients. The charity’s Dr Sam Godfrey said the results were incredibly exciting. “What this new drug has done is it’s found a way of drugging the undruggable.
“We are finally seeing progress in pancreatic cancer which is so long overdue.”
Dr Wungki Park, from Memorial Sloan Kettering Cancer Center in the US, who is involved in the trial, said: “We are beginning to see not only a higher percentage of tumour response rates, but also deeper responses and a near doubling in the duration of disease control, which may eventually translate into longer survival.”
Daraxonrasib has already been approved in the US. It works by locking on to and shutting off certain mutations, called RAS, found in most pancreatic cancers that drive tumour growth. Dozens of other cancers, including lung and ovarian, can have similar mutations.
Doctors stress it should not be seen as a cure, and it is unclear how long the effect might last. An independent expert noted that the trial involved only 61 patients and had no randomised control group. Dr Godfrey said: “Cancer can come back and even if scans show there is no sign of it, you don’t necessarily know you are cancer-free until more time has passed.”
Pancreatic cancer has the lowest survival rate of all common cancers in the UK. There are 11,500 diagnoses of the disease in Britain each year and around 10,200 deaths, according to Cancer Research UK.
POPULAR
- Abuja court remands 11 Malians over alleged kidnapping, human trafficking
- Mob beats accident survivor to death, burns car in Osun
- APGA adopts Tinubu as 2027 presidential candidate
- VeryDarkMan mocks Seyi Tinubu over recruitment of Obi Cubana, Arewa influencers
- Jimmy Odukoya barred from church affairs pending December 1 hearing
Rifnote
Loading your desk